Apr 27th 2020
  • Share:

National Medical Director Dr. Peter Coleman Voted Top Addiction Doc

Richmond Magazine’s annual physician poll honors Dr. Coleman for the seventh consecutive year in the category of Addiction Medicine.

The Coleman Institute for Addiction Medicine, a BayMark Health Services company, is honored to have National Medical Director and company founder Dr. Peter Coleman voted a Top Doc in Addiction Medicine for 2020. Richmond Magazine introduced the category of Addiction Medicine into its Top Docs feature for the first time in 2014. Since then, Dr. Coleman has been selected every year as one of the top 5 addiction specialists based on voting by other medical professionals, indicating his continued excellence in the field.

An innovative center for addiction treatment, The Coleman Institute is a highly effective, medically-supervised detoxification treatment center for opioids, alcohol and benzodiazepines. The withdrawal management program, known as an Accelerated Opioid Detox, uses medication to comfortably and quickly remove opiates from a patient’s system. The combination of detoxification and long-term support, including Naltrexone therapy and ongoing case management, provides patients with an individualized pathway into recovery.

Dr. Coleman’s commitment to the field stems from his personal struggle with addiction. He shares his story to offer hope to others, and has dedicated his life to developing treatment protocols that help patients get into long-term recovery with Medication-Assisted Treatment (MAT) that does not rely on addictive substances.

“I’m humbled to be included among the outstanding physicians on this list, but even more so to have been blessed with the opportunity to help in the recoveries of so many people.” shares Dr. Coleman. “Unfortunately, there remains a huge need for evidence-based addiction treatment programs, and I want to continue to do my part in providing compassionate solutions to those in need.”

For more information on The Coleman Institute and the Coleman Method for outpatient opioid detoxification, please visit:


About the Coleman Method:

The Coleman Institute provides detox services using the Coleman Method in Richmond, Virginia.  Many other medical practices across the country also provide similar detox services in affiliation with the Coleman Institute for Addiction Medicine.

Established in 1998, The Coleman Institute developed a unique and customizable approach to assisting patients in overcoming their physical dependency on drugs and then accessing the long-term support resources needed to maintain their sobriety.

The Coleman Method for accelerated opioid detox has helped thousands of patients detoxify and recover from the effects of heroin use and other opioids such as OxyContin®, Percocet® and Vicodin®. It enables 98% of patients to successfully complete their detox and begin Naltrexone therapy.

Besides Richmond, the Coleman Method is available at 11 offices nationwide: Atlanta, Austin, Cherry Hill, Dallas, Denver, Phoenix, Seattle, Tampa, Northern New Jersey (Fair Lawn), Southern California, and Northern California.


About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to more than 53,000 patients in recovery from substance use disorder across the United States and Canada. Our outpatient programs deliver medically supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances.

The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient office-based buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

CATEGORY: The Coleman Institute
Now Available: BayMark's 2023 Treatment Outcomes ReportGet the Whitepaper